Loading…
BioNexus Gene Lab Corp. is projected to decline to $1.28 by 2027, a -11% move from its current price of $1.43. BGLC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.38 | $1.43 | $1.48 | -0.03% |
| Aug 6 | $1.36 | $1.43 | $1.51 | -0.07% |
| Aug 7 | $1.34 | $1.43 | $1.52 | -0.10% |
| Aug 8 | $1.33 | $1.43 | $1.54 | -0.13% |
| Aug 9 | $1.31 | $1.43 | $1.55 | -0.17% |
| Aug 10 | $1.30 | $1.43 | $1.56 | -0.20% |
| Aug 11 | $1.29 | $1.43 | $1.57 | -0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.29 | $1.43 | $1.57 | -0.23% |
| Week 2 | $1.24 | $1.42 | $1.64 | -0.46% |
| Week 3 | $1.20 | $1.42 | $1.68 | -0.70% |
| Week 4 | $1.16 | $1.42 | $1.73 | -0.93% |
| Week 5 | $1.13 | $1.41 | $1.76 | -1.16% |
| Week 6 | $1.11 | $1.41 | $1.80 | -1.39% |
| Week 7 | $1.08 | $1.41 | $1.83 | -1.61% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioNexus Gene Lab Corp. and its subsidiaries focus on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding.
It offers polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process. The company's products are used in producing finished goods such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing.
It develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers. BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
BioNexus Gene Lab Corp. (BGLC) trades at $1.37 and has a market capitalization of $3.31M, ranking 5189.
The near-term price path is neutral, with 2026 forecast min $1.37, avg $1.37, max $1.64 and ROI 0, sentiment NEUTRAL.
Longer horizon forecasts show varying outcomes, including 2030 min $0.7852, avg $1.19, max $1.95 (ROI -13.3%), 2040 min $1.09, avg $2.22, max $4.49 (ROI 61.9%), and 2050 min $1.26, avg $2.80, max $6.38 (ROI 104.1%), with sentiments ranging from NEUTRAL to BULLISH.
A major floor 67.8% below — a decisive break under it would weaken the trend.
The nearest floor, 7.7% below — buyers have tended to step in here.
The nearest ceiling, 82.5% above — a clean break opens room to run.
A major ceiling 112.6% above — clearing it would confirm fresh momentum.
Key BGLC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BGLC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.34 | Buy | $1.36 | Buy |
| MA 10 | $1.46 | Sell | $1.45 | Sell |
| MA 20 | $1.62 | Sell | $1.60 | Sell |
| MA 50 | $1.98 | Sell | $1.87 | Sell |
| MA 100 | $2.10 | Sell | $2.18 | Sell |
| MA 200 | $2.97 | Sell | $2.76 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 25.13 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -120.67 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -21.43 | Sell |
| Bollinger %B (20,2) | 0.14 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -1.30 | Sell |
| Awesome (5,34) | -0.53 | Sell |
| Ultimate (7,14,28) | 8.73 | Buy |
| Momentum (10) | -0.34 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 1.28 | Buy |
| ADX (14) | 32.86 | Sell |
| ATR (14) | 0.06 | Info |
The 30-day technical picture is NEUTRAL. RSI14 is 30, SMA50 is $2.04, and SMA200 is $3.07.
The current price is $1.37 with support at $1.37 and resistance at $2.61. The thirty-day trading range spans from $1.02 to $1.84, and annualized volatility is 90%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.32 | $1.43 | $1.71 | 0% | Neutral | |
| $0.9837 | $1.28 | $1.77 | -11% | Neutral | |
| $1.01 | $1.37 | $1.99 | -4% | Neutral | |
| $0.8263 | $1.15 | $1.74 | -19% | Bearish | |
| $0.8711 | $1.25 | $1.95 | -12% | Neutral | |
| $1.09 | $1.62 | $2.59 | +13% | Neutral | |
| $1.09 | $1.65 | $2.71 | +15% | Neutral | |
| $1.12 | $1.74 | $2.93 | +22% | Bullish | |
| $1.04 | $1.65 | $2.82 | +15% | Neutral | |
| $0.9216 | $1.50 | $2.61 | +5% | Neutral | |
| $1.29 | $2.33 | $4.39 | +63% | Bullish | |
| $1.40 | $3.05 | $6.39 | +113% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.32 | $1.43 | $1.69 | +0.00% |
| September 2026 | $1.13 | $1.35 | $1.67 | -5.45% |
| October 2026 | $1.15 | $1.39 | $1.74 | +2.61% |
| November 2026 | $1.14 | $1.39 | $1.76 | +0.21% |
| December 2026 | $1.09 | $1.34 | $1.71 | -3.92% |
Click any year to see its month-by-month BGLC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect BGLC to range from $1.32 to $1.71 through 2026. The $1.43 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The BGLC price prediction for 2027 points to an average of $1.28 (low $0.9837, high $1.77) — a potential decline of -11% on today's $1.43. Price action looks broadly range-bound.
In 2028, BGLC is projected to trade between $1.01 and $1.99, averaging $1.37 — a potential decline of -4% from today's $1.43. That is up +7% on the projected 2027 average. A consolidation phase looks the most probable path here.
BioNexus Gene Lab Corp.'s 2029 outlook centres on $1.15, within a $0.8263 to $1.74 range. That is -16% versus the projected 2028 average. That marks a -19% change versus current levels. A cyclical pullback looks likely — prices rarely move in a straight line.
By 2030, BGLC could reach as high as $1.95, with a base case around $1.25 and support toward $0.8711 — roughly -12% from $1.43. A consolidation phase looks the most probable path here.
Expect BGLC to range from $1.09 to $2.59 through 2031. The $1.62 average target implies a +13% move from current prices. That is up +29% on the projected 2030 average. Price action looks broadly range-bound.
The BGLC price prediction for 2032 points to an average of $1.65 (low $1.09, high $2.71) — a potential gain of +15% on today's $1.43. A consolidation phase looks the most probable path here.
In 2033, BGLC is projected to trade between $1.12 and $2.93, averaging $1.74 — a potential gain of +22% from today's $1.43. That is up +6% on the projected 2032 average. Momentum favours further upside here.
BioNexus Gene Lab Corp.'s 2034 outlook centres on $1.65, within a $1.04 to $2.82 range. That is -6% versus the projected 2033 average. That marks a +15% change versus current levels. A consolidation phase looks the most probable path here.
By 2035, BGLC could reach as high as $2.61, with a base case around $1.50 and support toward $0.9216 — roughly +5% from $1.43. Price action looks broadly range-bound.
Expect BGLC to range from $1.29 to $4.39 through 2040. The $2.33 average target implies a +63% move from current prices. That is up +56% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The BGLC price prediction for 2050 points to an average of $3.05 (low $1.40, high $6.39) — a potential gain of +113% on today's $1.43. Momentum favours further upside here.
Investing $1,000 in BGLC today (≈ 699.300699 BGLC) could be worth
$2,129.63
+$1,129.63 (+113%) by 2050 · US Dollar
Based on the average projected BGLC price of $3.05 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BGLCwould be worth at today's price.
$1,000 invested in BGLC on Jul 31, 2025 (≈ 144.300148 BGLC) would be worth
$206.35
-$793.65 (-79.4%) today · 0.21× · US Dollar
Based on a BGLC entry price of $6.93 vs. today's $1.43.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.51 | $947.02 | -5.3% |
| 1 month ago | $2 | $715 | -28.5% |
| 3 months ago | $2.08 | $687.83 | -31.2% |
| 6 months ago | $2.83 | $506.19 | -49.4% |
| 1 year ago | $6.93 | $206.35 | -79.4% |
| All time (5.0y) ago | $153.6 | $9.31 | -99.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BGLC forecast.
Our base-case forecast reaches $2.90 around 2050.
Implied market cap at $2.90: $7.01M
Across the multi-year forecast, the outlook moves from neutral in 2026 to bullish by 2033 and through 2050. The 2030 forecast shows min $0.7852, avg $1.19, max $1.95 with ROI -13.3% and sentiment NEUTRAL. The 2040 forecast shows min $1.09, avg $2.22, max $4.49 with ROI 61.9% and sentiment BULLISH.
The 2050 forecast shows min $1.26, avg $2.80, max $6.38 with ROI 104.1% and sentiment BULLISH.
These figures are estimates and not guarantees; risks include that near-term results can remain subdued and that long-run outcomes depend on factors not provided here.
Tap a question to reveal the answer.
The 2030 forecast shows min $0.7852, avg $1.19, max $1.95 with ROI -13.3% and sentiment NEUTRAL.
Forecasts show potential long-term upside, with 2050 avg $2.80 and ROI 104.1%, but near-term years such as 2027-2029 show mixed/negative returns.
Yes, the 2050 max forecast is $6.38 with ROI 104.1%, though this is not guaranteed.
For 2026, min $1.37, avg $1.37, max $1.64; ROI 0; sentiment NEUTRAL.
The 2040 forecast shows min $1.09, avg $2.22, max $4.49 with ROI 61.9 and sentiment BULLISH.
BioNexus Gene Lab Corp. Community Discussion
0Share your BioNexus Gene Lab Corp. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.